Document is current
Any future updates will be listed below
-
Authors
Vermersch, Patrick
Wagner, David
Mars, Lennart T.
Noelle, Randolph
Giovannoni, Gavin
-
Funding
Funding for this research was provided by:
Centre Hospitalier Universitaire de Lille
- License Information
-
More Information
Article History
Accepted: 29 October 2024
First Online: 29 November 2024
Declarations
:
: Patrick Vermersch has received honoraria and consulting fees from Biogen, Sanofi, Novartis, Teva, Merck, Roche, Imcyse, AB Science, BMS-Celgene, and Ad Scientiam and research support from Novartis, Sanofi, and Roche.David Wagner is the chief scientific officer and co-founder of Op-T, LLC.Lennart T. Mars has received research support and honoraria as speaker from Merck and Novartis.Randolph Noelle is the co-founder of ImmuNext, which has licensed an anti-CD40L to Sanofi that is in commercial development and is an inventor on anti-CD40L patents.Gavin Giovannoni has received compensation over the last five years for receiving research support or serving as a consultant or speaker from AbbVie, Actelion, Atara Bio, Biogen, Canbex, Celgene, EMD Serono, Japanese Tobacco, Sanofi, Genentech, GlaxoSmithKline, GW Pharma, Merck, Novartis, Roche, Synthon BV, and Teva.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: The authors declare no competing interests.
